Flutamide: dermatology and respect to evidence and safety

Universidade Federal de São Paulo (UNIFESP) Departamento de Dermatologia Unidade de Cosmiatria, Cirurgia e OncologiaUNIFESP, Depto. de Dermatologia Unidade de Cosmiatria, Cirurgia e OncologiaSciEL

Hyperandrogenism and skin: polycystic ovary syndrome and peripheral insulin resistance

The polycystic ovary syndrome is an extremely common endocrine disorder in women of chilbearing age. It is characterized by menstrual disturbance, hyperandrogenism and/or hyperandrogenemia. The primary pathophysiological defect is unknown, but important characteristics include insulin resistance, androgen excess and impaired gonadotropin dynamics. The most frequent clinical characteristics of polycystic ovary syndrome are associated with the pilosebaceous unit, such as hirsutism, acne, seborrhea and alopecia. Thus, the dermatologist may be responsible for making an early diagnosis of the syndrome, thus preventing delay in establishing preventive and therapeutic measures. The current management recommended for skin manifestations of polycystic ovary syndrome includes combined oral contraceptives, antiandrogens and insulin-sensitizing agents, besides changes in life style. This is a review article on diagnosis, pathophysiology and treatment of polycystic ovary syndrome. The authors emphasize that a clear understanding of pathophysiology of this syndrome, especially by dermatologists, is crucial for its preventive treatment through the different phases in the life of women.A síndrome do ovário policístico é distúrbio endócrino feminino, extremamente comum na idade reprodutiva. Caracteriza-se por anormalidades menstruais, hiperandrogenismo e/ou hiperandrogenemia. A principal alteração na fisiopatologia é desconhecida. Entretanto, parece que a resistência à insulina, o hiperandrogenismo e a alteração na dinâmica das gonadotropinas são os mais importantes mecanismos fisiopatológicos envolvidos. As características clínicas mais freqüentes da síndrome do ovário policístico estão relacionadas com a unidade pilossebácea, como hirsutismo, acne, seborréia e alopecia. Desse modo, o dermatologista pode ser responsável pelo diagnóstico precoce da síndrome, evitando o retardo na instituição de medidas terapêutico-preventivas. Atualmente, as drogas recomendadas para as manifestações cutâneas da síndrome do ovário policístico são os contraceptivos orais conjugados, antiandrógenos e sensibilizantes de insulina e, além disso, é geralmente recomendada a modificação no estilo de vida. Trata-se de artigo de revisão sobre diagnóstico, fisiopatologia e tratamento da síndrome do ovário policístico. Os autores enfatizam que o conhecimento da fisiopatologia dessa síndrome, principalmente pelos dermatologistas, é fundamental para seu tratamento preventivo, nas diferentes fases da vida da mulher.Universidade Federal de São Paulo (UNIFESP) Departamento de DermatologiaUNIFESP, Depto. de DermatologiaSciEL

DEVELOPMENT and ACCEPTABILITY of A NEW INTERNATIONAL QUALITY of LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE: BEAUTYQOL

Data Min Int, Geneva, SwitzerlandLab Sante Publ, Marseilles, FranceNatl Ctr Sci Res, Villeurbanne, FranceUniv Utah, Hlth Sci Ctr, Salt Lake City, UT USAUniversidade Federal de São Paulo, São Paulo, BrazilUniv Tokyo, Bunkyo Ku, Tokyo 113, JapanLOreal Int, Asnieres, FranceUniv Paris 06, Paris, FranceUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc

International development of the first quality of life instrument specific to cosmetology and physical appearance: the BeautyQol initiative

Data Mining Int, Geneva, SwitzerlandLab Sante Publ, Marseilles, FranceNatl Ctr Sci Res, Lyon, FranceUniversidade Federal de São Paulo, São Paulo, BrazilUniv Tokyo, Tokyo, JapanLoreal Int, Asnieres, FranceUniv Paris 06, Paris, FranceUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc

Papulose bowenoide dos genitais

BV UNIFESP: Teses e dissertaçõe

A double-blind, randomized, comparative study of two type a botulinum toxins in the treatment of primary axillary hyperhidrosis

BACKGROUND Botulinum toxin (BTX) is an effective treatment for primary axillary hyperhidrosis. in this study we used two toxins not bioequivalent: BOTOX (Allergan, Inc.) and Dysport (Beaufour Ipsen Biotech).OBJECTIVE the objective was to compare the efficacy, safety, and tolerability of BOTOX and Dysport in the treatment of primary axillary hyperhidrosis using a conversion factor of 1: 3, respectively.METHODS in a double-blind, randomized prospective study, 10 patients with primary axillary hyperhidrosis and sweat production exceeding 50mg/minute received 50U of BOTOX in one axilla and 150U of Dysport in the other. We performed Minor's test and gravimetry at 0 days, at 15 days, and monthly for 1 year.RESULTS No significant difference was observed in the sweating quantity at baseline. After 1 month all patients had achieved success for both axillae. the sweat rate was reduced by a mean of 97.7% for BOTOX and 99.4% for Dysport, without statistical difference. the duration of benefits was similar between both toxins, with a mean of 260 days for BOTOX and 290 days for Dysport, without statistical difference. the longest symptom-free interval was 12 months (5 patients, 55.6%).CONCLUSIONS BOTOX and Dysport presented similar levels of safety and efficacy in the treatment of primary axillary hyperhidrosis when a conversion factor of 1: 3 was used.Universidade Federal de São Paulo, Dept Dermatol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Dermatol, São Paulo, BrazilWeb of Scienc

PREVENTION OF ASTHMA BY KETOTIFEN IN INFANTS WITH ATOPIC-DERMATITIS

To evaluate the prophylactic effect of ketotifen against the onset of asthma we selected 121 infants with atopic dermatitis, without any history suggestive of asthma (cough and/or wheezing). Sixty-one children received ketotifen twice daily. Those who weighted less than 14 kg received 0.8 mg; 14 kg or more, 1.2 mg. Sixty children, a placebo syrup indistinguishable from the active syrup. Both groups, were followed for 1 year, with bimonthly evaluations. The criteria for onset of asthma were two different episodes of wheezing treated with bronchodilator drugs. Both groups were comparable regarding age, sex, weight, onset, and duration of atopic dermatitis and age at the onset of asthma. During the 1 year study, asthma was observed in eight children of the ketotifen group (13.1%) and in 25 children of the placebo group (41.6%) (P < .001). Side effects were negligible and routine laboratory tests disclosed no significant alterations. Ketotifen is a very useful drug for prevention of asthma in children with atopic dermatitis and total IgE more than 50 IU/mL.NATL PEDIAT HOSP,DEPT ALLERGOL,TOKYO,JAPANESCOLA PAULISTA MED SCH,DEPT PEDIAT,DIV ALLERGY & CLIN IMMUNOL,BR-04023 SAO PAULO,BRAZILKYOTO UNIV,SCH MED,DEPT PEDIAT,KYOTO 606,JAPANESCOLA PAULISTA MED SCH,DEPT DERMATOL,BR-04023 SAO PAULO,BRAZILDOI MEM HOSP,DEPT PEDIAT,TOKYO,JAPANNATL MINAMI FUKUOKA HOSP,DEPT PEDIAT,FUKUOKA,JAPANESCOLA PAULISTA MED SCH,DEPT PEDIAT,DIV ALLERGY & CLIN IMMUNOL,BR-04023 SAO PAULO,BRAZILESCOLA PAULISTA MED SCH,DEPT DERMATOL,BR-04023 SAO PAULO,BRAZILWeb of Scienc